Siva Hariprasad Kurma,Matteo Pavan,Tina C Wan,Balaram Pradhan,Marc López-Cano,Francisco Ciruela,Zhan-Guo Gao,John A Auchampach,Kenneth A Jacobson
{"title":"双位A3腺苷受体分子探针:正变构调节和非规范激活。","authors":"Siva Hariprasad Kurma,Matteo Pavan,Tina C Wan,Balaram Pradhan,Marc López-Cano,Francisco Ciruela,Zhan-Guo Gao,John A Auchampach,Kenneth A Jacobson","doi":"10.1021/acs.jmedchem.5c01985","DOIUrl":null,"url":null,"abstract":"1H-Imidazo[4,5-c]quinolin-4-amines are lipid-facing, positive allosteric modulators (PAMs) of the Gi-coupled A3 adenosine receptor (A3AR). Elongated amino-alkyl chains anchor these bitopic PAMs secondarily to anionic phospholipids in the membrane's inner leaflet. Varied terminal functionalities and introduced reporter groups, as well as N1-alkylation on the core heterocycle, substantially enhanced human A3AR agonist (Cl-IB-MECA) potency and efficacy in [35S]GTPγS binding and revealed ago-PAM activity. Docking calculations predicted N1-benzylation to reduce undesired orthosteric site binding. Fluorophores, biotin, click moieties, chemically reactive, and photouncaging groups were included. Compound 38 (MRS8435, 9-methylenes, 0.1-10 μM) achieved ∼300% agonist Emax without ago-PAM activity. 4-Methyl 36 and 4-iodo 46 substitution of N1-benzyl increased Cl-IB-MECA potency by 14.7- and 30.5-fold, respectively. 9-Methylene N1-benzyl derivatives 35 and 42 achieved high ago-PAM efficacy (∼77% Cl-IB-MECA Emax). Molecular dynamics simulations detected stable electrostatic phospholipid interactions while maintaining A3AR allosteric binding. Thus, we rationally expanded SAR of bitopic A3AR PAMs, including molecular probes.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"75 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bitopic A3 Adenosine Receptor Molecular Probes: Positive Allosteric Modulation and Noncanonical Activation.\",\"authors\":\"Siva Hariprasad Kurma,Matteo Pavan,Tina C Wan,Balaram Pradhan,Marc López-Cano,Francisco Ciruela,Zhan-Guo Gao,John A Auchampach,Kenneth A Jacobson\",\"doi\":\"10.1021/acs.jmedchem.5c01985\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"1H-Imidazo[4,5-c]quinolin-4-amines are lipid-facing, positive allosteric modulators (PAMs) of the Gi-coupled A3 adenosine receptor (A3AR). Elongated amino-alkyl chains anchor these bitopic PAMs secondarily to anionic phospholipids in the membrane's inner leaflet. Varied terminal functionalities and introduced reporter groups, as well as N1-alkylation on the core heterocycle, substantially enhanced human A3AR agonist (Cl-IB-MECA) potency and efficacy in [35S]GTPγS binding and revealed ago-PAM activity. Docking calculations predicted N1-benzylation to reduce undesired orthosteric site binding. Fluorophores, biotin, click moieties, chemically reactive, and photouncaging groups were included. Compound 38 (MRS8435, 9-methylenes, 0.1-10 μM) achieved ∼300% agonist Emax without ago-PAM activity. 4-Methyl 36 and 4-iodo 46 substitution of N1-benzyl increased Cl-IB-MECA potency by 14.7- and 30.5-fold, respectively. 9-Methylene N1-benzyl derivatives 35 and 42 achieved high ago-PAM efficacy (∼77% Cl-IB-MECA Emax). Molecular dynamics simulations detected stable electrostatic phospholipid interactions while maintaining A3AR allosteric binding. Thus, we rationally expanded SAR of bitopic A3AR PAMs, including molecular probes.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"75 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c01985\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c01985","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
1H-Imidazo[4,5-c]quinolin-4-amines are lipid-facing, positive allosteric modulators (PAMs) of the Gi-coupled A3 adenosine receptor (A3AR). Elongated amino-alkyl chains anchor these bitopic PAMs secondarily to anionic phospholipids in the membrane's inner leaflet. Varied terminal functionalities and introduced reporter groups, as well as N1-alkylation on the core heterocycle, substantially enhanced human A3AR agonist (Cl-IB-MECA) potency and efficacy in [35S]GTPγS binding and revealed ago-PAM activity. Docking calculations predicted N1-benzylation to reduce undesired orthosteric site binding. Fluorophores, biotin, click moieties, chemically reactive, and photouncaging groups were included. Compound 38 (MRS8435, 9-methylenes, 0.1-10 μM) achieved ∼300% agonist Emax without ago-PAM activity. 4-Methyl 36 and 4-iodo 46 substitution of N1-benzyl increased Cl-IB-MECA potency by 14.7- and 30.5-fold, respectively. 9-Methylene N1-benzyl derivatives 35 and 42 achieved high ago-PAM efficacy (∼77% Cl-IB-MECA Emax). Molecular dynamics simulations detected stable electrostatic phospholipid interactions while maintaining A3AR allosteric binding. Thus, we rationally expanded SAR of bitopic A3AR PAMs, including molecular probes.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.